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Abstract. Background: The stability and propagation of hepatitis C
virus (HCV) is dependent on a functional interaction between the
HCV genome and liver-expressed microRNA-122 (miR-122). Miravir-
sen is a locked nucleic acid-modiﬁed DNA phosphorothioate anti-
sense oligonucleotide that sequesters mature miR-122 in a highly
stable heteroduplex, thereby inhibiting its function.
Methods: In this phase 2a study at seven international sites, we eval-
uated the safety and efﬁcacy of miravirsen in 36 patients with
chronic HCV genotype 1 infection. The patients were randomly
assigned to receive ﬁve weekly subcutaneous injections of miravirsen
at doses of 3 mg, 5 mg, or 7 mg per kilogram of body weight or pla-
cebo over a 29-day period. They were followed until 18 weeks after
randomization.
Results: Miravirsen resulted in a dose-dependent reduction in HCV
RNA levels that endured beyond the end of active therapy. In the mir-
avirsen groups, the mean maximum reduction in HCV RNA level
(log10 IU per milliliter) from baseline was 1.2 (P = 0.01) for patients
receiving 3 mg per kilogram, 2.9 (P = 0.003) for those receiving 5mg
per kilogram, and 3.0 (P = 0.002) for those receiving 7 mg per
kilogram, as compared with a reduction of 0.4 in the placebo group.
During 14 weeks of follow-up after treatment, HCV RNA was not
detected in one patient in the 5-mg group and in four patients in
the 7-mg group. We observed no dose-limiting adverse events and
no escape mutations in the miR-122 binding sites of the HCV
genome.
Conclusions: The use of miravirsen in patients with chronic HCV
genotype 1 infection showed prolonged dose-dependent reductions
in HCV RNA levels without evidence of viral resistance. (Funded by
Santaris Pharma; ClinicalTrials.gov number, NCT01200420.)
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Journal of Hepatology 20
Keywords: HCV; miR-122; Antisense; DAA.
Received 28 May 2013; received in revised form 29 August 2013; accepted 30 August
2013
⇑ Corresponding author.
E-mail address: imj2001@med.cornell.edu (I.M. Jacobson).MicroRNAs are small non-coding RNAs encoded by the human
genome that transcriptionally and post-transcriptionally modify
gene expression. The microRNA-122 (miR-122) forms the domi-
nant microRNA in the liver and is exclusively expressed in hepa-
tocytes. It has been implicated in multiple different processes,
including lipid metabolism, cell differentiation, iron metabolism
and hepatic circadian regulation [1]. In 2005 Jopling and col-
leagues identiﬁed miR-122 as an essential co-factor for hepatitis
C virus (HCV) replication [2]. The 50 untranslated region (UTR) of
HCV is highly conserved across genotypes and contains two miR-
122 binding sites, disruption of which blocks HCV replication
through unknown mechanisms [3]. Miravirsen, a 15 nucleotide
long oligonucleotide complementary to miR-122, can form stable
heteroduplexes with miR-122 and interfere with HCV replication.
Whether miravirsen exerts its antiviral effects predominantly
through sequestration of available miR-122, indirectly through
disrupting lipid pathways essential to the viral lifecycle, or
through other mechanisms remains under active investigation.
Its efﬁcacy against chronic HCV infection was ﬁrst shown in stud-
ies in chimpanzees, the only natural HCV animal model. Chim-
panzees that received the highest, 5 mg/kg, dose through a
weekly infusion had a marked decrease in plasma and liver
HCV RNA [4], which led to clinical testing of miravirsen. Now
Janssen and colleagues report on their ﬁndings from a phase 2a
study in treatment naive non-cirrhotic patients chronically
infected with HCV genotype 1 [5]. They enrolled 36 patients
who were randomized to 5 weekly subcutaneous injections with
three different doses of miravirsen (3, 5 or 7 mg/kg) or placebo,
with the possibility of pegylated interferon (PegIFN) and ribavirin
(RBV) rescue at deﬁned time points after miravirsen completion
and at the investigator’s discretion. After the last injection of mir-
avirsen, patients were followed for an additional 14 weeks for
viral kinetics and adverse events. They found that HCV RNA
showed a dose-dependent decline, with 1 (11%) patient in the
5 mg/kg and 4 (44%) patients in the 7 mg/kg groups reaching
undetectable HCV RNA levels, all after the ﬁfth dose of miravir-
sen. Notably, the individual response curves shown by the
authors were quite variable, even with the highest dose. Three
of the patients whose HCV RNA became undetectable relapsed
4–5 weeks later and one patient went on to be treated with Peg-
IFN/RBV. The long term outcome in the remaining patient who
achieved an undetectable HCV RNA at study week 14 and
remained undetectable through week 18 was not reported.
Adverse events were generally mild with only injection site reac-
tions being likely related to miravirsen administration.
Treatment for chronic HCV, which until recently was plagued
by poor tolerability and suboptimal response rates, is undergoing14 vol. 60 j 227–228
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a profound paradigm shift with the development of HCV prote-
ase, polymerase and NS5A inhibitors and the demonstration of
extremely high rates of sustained virologic response with inter-
feron-free combination regimens. Although DAAs currently under
clinical investigation generally have high potency, all but nucleo-
tide polymerase inhibitors have low barriers to resistance and
therefore combination therapy appears necessary for most HCV
genotypes. In contrast to the rapid decline in HCV RNA level
within days after starting potent DAAs, there was a <2 log decline
at week 4 even with the highest dose of miravirsen. Given our
lack of understanding how HCV utilizes miR-122 in its life cycle
[6] and by what mechanisms miravirsen blocks HCV replication,
it is difﬁcult to account for the different kinetics. Apart from
being amongst the ﬁrst successful antisense oligonucleotide ther-
apies in man, the current study by Janssen and colleagues is nota-
ble for additional reasons. First, the strategy of targeting miR122
is distinct from that underlying the three major DAA classes
under investigation; in theory, it can be used complementary to
DAAs. Similar to strategies that interfere with cyclophilin A [7],
miravirsen is an example of the capacity for an inhibitor of a host
factor essential for the HCV life cycle to abrogate viremia with no
evidence of viral escape. Although theoretical escape mutants can
be engineered in vitro [8], the high barrier to resistance and the
duration of post-treatment viral suppression in some patients
(to the end of study in one patient), imply the possibility that
miravirsen could lead to viral eradication with a monotherapy.
To address this ambitious proposition, the authors mention that
longer duration studies with 12 weeks of miravirsen mono-
therapy are ongoing. Finally, given the highly conserved 50 UTR
and miravirsen’s ability to block replication of all HCV genotypes
in vitro [8], it is likely that the current results with genotype 1
patients will hold true across genotypes. This may make therapy
with miravirsen a potential approach for genotypes that may be
less susceptible to some of the DAAs in development.
Its attractive features and favorable short-term safety proﬁle
notwithstanding, antisense therapy warrants a note of caution.
MiR-122 modulates the expression of an estimated 200 hepato-
cyte proteins, some of which have been implicated in cholesterol
metabolism and cancer development. Although not conﬁrmed in
the setting of HCV infection, low miR-122 levels expressed in
hepatocellular carcinomas (HCCs) appear to predict a poor prog-
nosis [9], as acknowledged by the authors, and decrease suscep-
tibility to sorafenib in cell culture[10]. Furthermore germline
deletion of miR-122 was recently shown to lead to steatohepati-
tis and spontaneous HCC development in mice [11,12]. The lower
serum cholesterol levels observed in patients after miravirsen
administration [5] illustrate that other miR-122 targets are also
affected during therapy. In a population at increased risk for
developing HCC, these experimental ﬁndings warrant careful
scrutiny during further clinical development.
The potential beneﬁts of miravirsen must be weighed in the
context of the very high rates of sustained virologic response in
recent studies of oral DAA combination regimens. The require-
ment for parenteral administration is a potential drawback, but228 Journal of Hepatology 201this may be mitigated if the authors prove to be correct in their
suggestion that the pharmacokinetic proﬁle of the drug makes
once monthly dosing feasible. Overall, the results of Janssen
et al. represent an intriguing proof of concept for a new class of
host factor antagonists that combine antiviral potency with a
high barrier to resistance. The formulation of a developmental
pathway for miravirsen may prove to be challenging in the cur-
rent environment, but it deserves further study and could have
a therapeutic role, particularly if DAA combinations leave unmet
needs in some patient populations.Conﬂict of interest
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